GMA News
Vaxine eyes COVID-19 vaccine trial in the Philippines –DOST
The World Health Organization's Solidarity Trial Phase 3 is scheduled to commence in the Philippines in December, with the WHO expected to provide details on trial sites soon.
Australian firm Vaxine Pty. Ltd. has also expressed interest in conducting a COVID-19 vaccine clinical trial and potential local manufacturing in the Philippines.
Vaxine has developed a vaccine that combines viral proteins with an immune-stimulating adjuvant, and its Phase 1 clinical trial began mid-this year.
Separately, the DOST's Vaccine Expert Panel has approved Chinese company Sinovac's vaccine for clinical trials, pending further approvals from the Ethics Board and FDA.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The Vaccine Expert Panel (VEP) in the Philippines is currently evaluating an application from Australian firm Clover Biopharmaceuticals for COVID-19 vaccine clinical trials.
Read more →
The Department of Health (DOH) announced that the third phase of the World Health Organization (WHO) Solidarity Trial for potential COVID-19 vaccines in the Philippines is scheduled to begin in December.
Read more →
Sinovac Biotech has applied to the FDA for approval to conduct Phase III clinical trials for its COVID-19 vaccine candidate in the Philippines.
Read more →
Senate President Pro Tempore Ralph Recto has proposed the appointment of a "vaccine czar" by Malacañang to guarantee access to COVID-19 vaccines for 110 million Filipinos.
Read more →
Philippine Ambassador to Beijing Jose Santiago Sta. Romana announced that China has not imposed any conditions for the Philippines to access its COVID-19 vaccines currently under development.
Read more →